ClinicalTrials.gg
CompletedNCT01610414Updated Jan 23, 2018Results posted

Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A

A Phase 3 interventional study of Herpes Zoster vaccine GSK1437173A and Placebo in Herpes Zoster, sponsored by GlaxoSmithKline. Completed at 178 sites in 28 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-01-23.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,877
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.

Enrollment
8th of 46
1,877 · median 239
Started
2012
the only one that year
Phase 3
22 of 46
2 open now
Registered
7th of 46
by date
Lead sponsor
26 of 46
GlaxoSmithKline

Among the 46 studies testing shingrix in Herpes Zoster, this one is the 8th largest by enrollment, is the only one that started in 2012, is one of 22 in phase 3, and was the 7th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About shingrix

shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing shingrix in Herpes Zoster, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of GSK Biologicals' vaccine GSK1437173A in the prevention of Herpes zoster (HZ) in autologous haematopoietic cell transplant recipients 18 years of age and older. To this end, the study will evaluate vaccine efficacy (VE) of the GSK1437173A vaccine, administered on a 2-dose schedule, compared to placebo in reducing the risk of developing HZ in this population.

03

Conditions studied

  • Herpes Zoster

Browse trials for

Keywords

  • Observer-blind
  • Efficacy
  • Immunogenicity
  • Vaccination
  • Safety
  • Adult autologous haematopoietic cell transplant recipients
  • Herpes Zoster
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Study entry (enrollment) occurs at the Pre-vaccination visit.

  • Subjects who the investigator believes can and will comply with the requirements of the protocol.
  • Written obtained from the subject.
  • A male or female aged 18 years or older at the time of study entry.
  • Has undergone or will undergo HCT within 50-70 days prior to the first vaccination with the study vaccine/placebo, and there are no plans for additional HCTs.
  • Female subjects of non- may be enrolled in the study. For this study population, non-childbearing potential is defined as current tubal ligation, hysterectomy, ovariectomy or .

OR Female subjects of childbearing potential may be enrolled in the study, if the subject has practiced adequate for 30 days prior to vaccination with the study vaccine/placebo, and has a negative pregnancy test on the day of vaccination, and has agreed to continue adequate contraception during the entire treatment period and for 12 months after completion of the vaccination series (i.e., until Month 13).

Exclusion criteria

Exclusion Criteria:

  • Use of any or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine/placebo, or planned use during the study period. However, the investigational use of a registered or non-registered product to treat the subject's underlying disease for which the HCT was undertaken, or a complication of the underlying disease, is allowed.
  • Previous vaccination against HZ or varicella within the 12 months preceding the first dose of study vaccine/placebo.
  • Planned administration during the study of a HZ vaccine other than the study vaccine.
  • Occurrence of a varicella or HZ episode by clinical history within the 12 months preceding the first dose of study vaccine/placebo.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine or study material and equipment.
  • Prophylactic antiviral therapy with activity against Varicella Zoster Virus (VZV) expected to last more than 6 months after transplantation.
  • Administration and/or planned administration of a vaccine not foreseen by the study protocol between HCT and 30 days after the last dose of study vaccine/placebo. However, licensed non-replicating vaccines may be administered up to 8 days prior to dose 1and/or 2, and/or at least 14 days after any dose of study vaccine/placebo.
  • infection by clinical history.
  • Pregnant or lactating female.
  • Female planning to become pregnant or planning to discontinue precautions (if of ) before Month 13 (i.e., one year after the last dose of study vaccine/placebo).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,877 participants (actual)

Study arms

  • Experimental
    GSK1437173A Group

    Subjects received 2 doses of the candidate HZ vaccine GSK 1437173A, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 1 Month schedule.

    Biological: Herpes Zoster vaccine GSK1437173A

  • Placebo comparator
    Placebo Group

    Subjects received 2 doses of placebo (saline solution), administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 1 Month schedule.

    Biological: Placebo

Interventions

  • 2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm

  • BiologicalPlacebo

    2 doses administered IM in deltoid region of non-dominant arm

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Confirmed Herpes Zoster (HZ) Episode

    A suspected case of HZ was defined as (1) a new rash characteristic of HZ (e.g., unilateral, dermatomal and accompanied by pain broadly defined to include allodynia, pruritus or other sensations), or a vesicular rash suggestive of VZV infection regardless of the distribution, and no alternative diagnosis; or (2) a clinical presentation (symptoms and/or signs) and specific laboratory findings\* suggestive of VZV infection in the absence of characteristic HZ or VZV rash. A suspected case of HZ was confirmed either: by Polymerase Chain Reaction (PCR) or by the HZ Ascertainment Committee (HZAC), consisting of physicians with HZ expertise.

    Time frame: From Month 0 until the cut-off date for final analysis (median follow-up was of 21 months)

Secondary outcomes

  1. Duration of 'Worst' HZ-associated Pain

    Duration of HZ-associated pain rated as 3 or greater on the 'worst pain' Zoster Brief Pain Inventory (ZBPI) question, following the onset of a confirmed HZ rash over the entire pain reporting period in subjects with confirmed HZ; presented as T (day) \[=the sum of follow-up period (for subjects without severe worst pain T is 1, for subjects with severe worst pain T is the duration of severe worst pain) expressed in days\].

    Time frame: From Month 0 until study end (4 years approximately), from the onset of a confirmed HZ rash over the entire pain reporting period

  2. Number of Subjects With Confirmed HZ-associated Complications

    This analysis excluded complications that were linked to a confirmed HZ case that occurred after the start of the relapse treatment.

    Time frame: From Month 0 until the cut-off date for final analysis (median follow-up was of 21 months)

  3. Number of Subjects With Postherpetic Neuralgia (PHN)

    This analysis excluded PHN episodes that were linked to a confirmed HZ case that occurred after the start of the relapse treatment.

    Time frame: From Month 0 until study end (21 months median follow-up)

  4. Antigen-glycoprotein E (gE) Antibody Concentrations in a Sub-cohort of Subjects

    Anti-gE antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL). The seropositivity cut-off value was greater than or equal to (≥) 97 mIU/mL.

    Time frame: At Months 0, 1, 2, 13 and 25

  5. Number of Subjects With Any and Grade 3 Solicited Local Symptoms

    Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.

    Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses

  6. Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms

    Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever \[defined as axillary/tympanic temperature equal to or above 37.5 degrees Celsius (°C) or rectal temperature equal to or above 38.0 °C\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.5 °C. Related = symptom assessed by the investigator as related to the vaccination.

    Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses

  7. Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

    Time frame: During the 30-day (Days 0-29) post-vaccination period

  8. Number of Subjects With Any and Related Potential Immune Mediated Diseases (pIMDs)

    Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

    Time frame: From Month 0 up to 365 days post last vaccination

  9. Number of Subjects With Any Relapse

    Relapse was defined as the occurrence of the underlying malignancy or disease for which the HCT was undertaken.

    Time frame: From Month 0 until study end (approximate median of 29 months follow-up - minimum 1 year and maximum 4 years)

  10. Number of Subjects With Any Serious Adverse Events (SAEs) and Related SAEs to GSK Study Vaccine/Placebo

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. This enpoint also presents SAES related to the GSK study vaccine/placebo.

    Time frame: From Month 0 until 365 days post last vaccination (approximate median of 29 months follow-up - minimum 1 year and maximum 4 years)

  11. Number of Subjects With Fatal SAEs and SAEs Related to Study Participation or to a GSK Concomitant Medication or Vaccination

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. This endpoint presents fatal SAEs and SAEs related to study participation or to a concurrent GSK medication/vaccine.

    Time frame: From the Pre-vaccination visit (Up to 110 days prior Month 0) until study end (approximate median of 29 months follow-up minimum 1 year and maximum 4 years)

07

Results

Posted Jan 23, 2018

Participant flow

Study Start - Month 13
Participant flow — Study Start - Month 13
MilestoneGSK1437173A GroupPlacebo Group
Started922924
Completed807795
Not completed115129
Withdrew: Serious adverse event6567
Withdrew: Adverse event1414
Withdrew: Protocol violation31
Withdrew: Withdrawal by subject2330
Withdrew: Migrated/moved from study area24
Withdrew: Lost to follow-up46
Withdrew: Suspected hz episode13
Withdrew: Other reasons for withdrawal34
Month 13 - Month 25
Participant flow — Month 13 - Month 25
MilestoneGSK1437173A GroupPlacebo Group
Started922924
Completed857854
Not completed6570
Withdrew: Serious adverse event3538
Withdrew: Adverse event84
Withdrew: Withdrawal by subject78
Withdrew: Migrated/moved from study area42
Withdrew: Protocol violation02
Withdrew: Lost to follow-up59
Withdrew: Other reasons for withdrawal67
After Month 25
Participant flow — After Month 25
MilestoneGSK1437173A GroupPlacebo Group
Started922924
Completed874871
Not completed4853
Withdrew: Study end not reached4853

Outcome measures

PrimaryNumber of Subjects With Confirmed Herpes Zoster (HZ) Episode

A suspected case of HZ was defined as (1) a new rash characteristic of HZ (e.g., unilateral, dermatomal and accompanied by pain broadly defined to include allodynia, pruritus or other sensations), or a vesicular rash suggestive of VZV infection regardless of the distribution, and no alternative diagnosis; or (2) a clinical presentation (symptoms and/or signs) and specific laboratory findings\* suggestive of VZV infection in the absence of characteristic HZ or VZV rash. A suspected case of HZ was confirmed either: by Polymerase Chain Reaction (PCR) or by the HZ Ascertainment Committee (HZAC), consisting of physicians with HZ expertise.

Time frame:
From Month 0 until the cut-off date for final analysis (median follow-up was of 21 months)
Reported as:
Count of participants · Participants
Number of Subjects With Confirmed Herpes Zoster (HZ) Episode
ParticipantsGSK1437173A GroupPlacebo Group
Number of Subjects With Confirmed Herpes Zoster (HZ) Episode49135
Statistical analysis
  • GSK1437173A Group vs Placebo Group · Poisson method · p = <0.0001 · Vaccine efficacy: 68.17 · 95% CI 55.56 to 77.53
SecondaryDuration of 'Worst' HZ-associated Pain

Duration of HZ-associated pain rated as 3 or greater on the 'worst pain' Zoster Brief Pain Inventory (ZBPI) question, following the onset of a confirmed HZ rash over the entire pain reporting period in subjects with confirmed HZ; presented as T (day) \[=the sum of follow-up period (for subjects without severe worst pain T is 1, for subjects with severe worst pain T is the duration of severe worst pain) expressed in days\].

Time frame:
From Month 0 until study end (4 years approximately), from the onset of a confirmed HZ rash over the entire pain reporting period
Reported as:
Number · T (day)
Duration of 'Worst' HZ-associated Pain
T (day)GSK1437173A GroupPlacebo Group
Duration of 'Worst' HZ-associated Pain892.06275.0
SecondaryNumber of Subjects With Confirmed HZ-associated Complications

This analysis excluded complications that were linked to a confirmed HZ case that occurred after the start of the relapse treatment.

Time frame:
From Month 0 until the cut-off date for final analysis (median follow-up was of 21 months)
Reported as:
Count of participants · Participants
Number of Subjects With Confirmed HZ-associated Complications
ParticipantsGSK1437173A GroupPlacebo Group
Number of Subjects With Confirmed HZ-associated Complications313
SecondaryNumber of Subjects With Postherpetic Neuralgia (PHN)

This analysis excluded PHN episodes that were linked to a confirmed HZ case that occurred after the start of the relapse treatment.

Time frame:
From Month 0 until study end (21 months median follow-up)
Reported as:
Count of participants · Participants
Number of Subjects With Postherpetic Neuralgia (PHN)
ParticipantsGSK1437173A GroupPlacebo Group
Number of Subjects With Postherpetic Neuralgia (PHN)19
SecondaryAntigen-glycoprotein E (gE) Antibody Concentrations in a Sub-cohort of Subjects

Anti-gE antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL). The seropositivity cut-off value was greater than or equal to (≥) 97 mIU/mL.

Time frame:
At Months 0, 1, 2, 13 and 25
Reported as:
Geometric mean · mIU/mL
Antigen-glycoprotein E (gE) Antibody Concentrations in a Sub-cohort of Subjects
mIU/mLGSK1437173A GroupPlacebo Group
Anti-gE, Month 0762.8 (568.6 to 1023.5)555.0 (404.3 to 761.8)
Anti-gE, Month 11844.2 (1282.2 to 2652.4)556.6 (407.3 to 760.6)
Anti-gE, Month 212753.2 (7973.0 to 20399.4)443.8 (330.8 to 595.4)
Anti-gE, Month 133183.8 (1869.8 to 5421.2)503.6 (307.8 to 824.1)
Anti-gE, Month 252819.0 (1387.1 to 5729.1)527.0 (274.3 to 1012.6)
SecondaryNumber of Subjects With Any and Grade 3 Solicited Local Symptoms

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.

Time frame:
During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Reported as:
Count of participants · Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
ParticipantsGSK1437173A GroupPlacebo Group
Any Pain, Dose 168856
Grade 3 Pain, Dose 1593
Any Redness, Dose 11875
Grade 3 Redness, Dose 170
Any Swelling, Dose 11017
Grade 3 Swelling, Dose 110
Any Pain, Dose 263845
Grade 3 Pain, Dose 2630
Any Redness, Dose 22314
Grade 3 Redness, Dose 2240
Any Swelling, Dose 21323
Grade 3 Swelling, Dose 2120
Any Pain, Across doses75683
Grade 3 Pain, Across doses993
Any Redness, Across doses3019
Grade 3 Redness, Across doses280
Any Swelling, Across doses1689
Grade 3 Swelling, Across doses130
SecondaryNumber of Subjects With Any, Grade 3 and Related Solicited General Symptoms

Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever \[defined as axillary/tympanic temperature equal to or above 37.5 degrees Celsius (°C) or rectal temperature equal to or above 38.0 °C\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.5 °C. Related = symptom assessed by the investigator as related to the vaccination.

Time frame:
During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Reported as:
Count of participants · Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
ParticipantsGSK1437173A GroupPlacebo Group
Any Fatigue, Dose 1356282
Grade 3 Fatigue, Dose 13016
Related Fatigue, Dose 112455
Any Gastrointestinal, Dose 1150134
Grade 3 Gastrointestinal, Dose 167
Related Gastrointestinal, Dose 14122
Any Headache, Dose 1156121
Grade 3 Headache, Dose 123
Related Headache, Dose 15132
Any Myalgia, Dose 1340170
Grade 3 Myalgia, Dose 12211
Related Myalgia, Dose 117050
Any Shivering, Dose 111673
Grade 3 Shivering, Dose 166
Related Shivering, Dose 15627
Any Temperature, Dose 16028
Grade 3 Temperature, Dose 110
Related Temperature, Dose 1277
Any Fatigue, Dose 2395212
Grade 3 Fatigue, Dose 24820
Related Fatigue, Dose 215341
Any Gastrointestinal, Dose 214298
Grade 3 Gastrointestinal, Dose 21312
Related Gastrointestinal, Dose 25113
Any Headache, Dose 223288
Grade 3 Headache, Dose 2248
Related Any Headache, Dose 29520
Any Myalgia, Dose 2374153
Grade 3 Myalgia, Dose 2429
Related Myalgia, Dose 220847
Any Shivering, Dose 218559
Grade 3 Shivering, Dose 2291
Related Shivering, Dose 210216
Any Temperature, Dose 215028
Grade 3 Temperature, Dose 221
Related Temperature, Dose 288
Any Fatigue, Across doses508340
Grade 3 Fatigue, Across doses6631
Related Fatigue, Across doses21079
Any Gastrointestinal, Across doses238183
Grade 3 Gastrointestinal, Across doses1817
Related Gastrointestinal, Across doses7930
Any Headache, Across doses302166
Grade 3 Headache, Across doses2610
Related Headache, Across doses12346
Any Myalgia, Across doses484234
Grade 3 Myalgia, Across doses5619
Related Myalgia, Across doses27983
Any Shivering, Across doses237115
Grade 3 Shivering, Across doses357
Related Shivering, Across doses13138
Any Temperature, Across doses18350
Grade 3 Temperature, Across doses31
Related Temperature, Across doses10115
SecondaryNumber of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

Time frame:
During the 30-day (Days 0-29) post-vaccination period
Reported as:
Count of participants · Participants
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
ParticipantsGSK1437173A GroupPlacebo Group
Any AE(s)360353
Grade 3 AE(s)6047
Related AE(s)3123
SecondaryNumber of Subjects With Any and Related Potential Immune Mediated Diseases (pIMDs)

Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

Time frame:
From Month 0 up to 365 days post last vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Any and Related Potential Immune Mediated Diseases (pIMDs)
ParticipantsGSK1437173A GroupPlacebo Group
Any pIMDs138
Related pIMDs30
SecondaryNumber of Subjects With Any Relapse

Relapse was defined as the occurrence of the underlying malignancy or disease for which the HCT was undertaken.

Time frame:
From Month 0 until study end (approximate median of 29 months follow-up - minimum 1 year and maximum 4 years)
Reported as:
Count of participants · Participants
Number of Subjects With Any Relapse
ParticipantsGSK1437173A GroupPlacebo Group
Number of Subjects With Any Relapse239253
SecondaryNumber of Subjects With Any Serious Adverse Events (SAEs) and Related SAEs to GSK Study Vaccine/Placebo

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. This enpoint also presents SAES related to the GSK study vaccine/placebo.

Time frame:
From Month 0 until 365 days post last vaccination (approximate median of 29 months follow-up - minimum 1 year and maximum 4 years)
Reported as:
Count of participants · Participants
Number of Subjects With Any Serious Adverse Events (SAEs) and Related SAEs to GSK Study Vaccine/Placebo
ParticipantsGSK1437173A GroupPlacebo Group
Any SAEs, up to Month 13263241
Related SAEs, up to Month 1334
Any SAEs, up to Study End329310
SecondaryNumber of Subjects With Fatal SAEs and SAEs Related to Study Participation or to a GSK Concomitant Medication or Vaccination

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. This endpoint presents fatal SAEs and SAEs related to study participation or to a concurrent GSK medication/vaccine.

Time frame:
From the Pre-vaccination visit (Up to 110 days prior Month 0) until study end (approximate median of 29 months follow-up minimum 1 year and maximum 4 years)
Reported as:
Count of participants · Participants
Number of Subjects With Fatal SAEs and SAEs Related to Study Participation or to a GSK Concomitant Medication or Vaccination
ParticipantsGSK1437173A GroupPlacebo GroupNo Group
Fatal SAEs1181240
Related SAEs37430

Adverse events

Collected over Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited adverse events (AEs): during the 30-day (Days 0-29) post-vaccination period; SAEs: during the entire study period, up to 365 days post last vaccination (4 years approximately).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GSK1437173A Group118/922 (12.8%)329/922 (35.7%)813/922 (88.2%)
Placebo Group124/924 (13.4%)310/924 (33.5%)485/924 (52.5%)
Most frequent serious events
Showing 10 of 371
Most frequent serious events
EventGSK1437173A GroupPlacebo Group
Plasma cell myelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)90/92270/924
PneumoniaInfections and infestations55/92241/924
SepsisInfections and infestations15/9228/924
Febrile neutropeniaBlood and lymphatic system disorders14/92212/924
Diffuse large b-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)13/92211/924
LymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)13/92213/924
B-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)12/92211/924
Acute kidney injuryRenal and urinary disorders12/9224/924
InfluenzaInfections and infestations11/9227/924
PyrexiaGeneral disorders10/9228/924
Most frequent other events
Most frequent other events
EventGSK1437173A GroupPlacebo Group
PainGeneral disorders757/92284/924
FatigueGeneral disorders509/922341/924
MyalgiaMusculoskeletal and connective tissue disorders485/922236/924
ErythemaSkin and subcutaneous tissue disorders304/92211/924
HeadacheNervous system disorders304/922170/924
ChillsGeneral disorders238/922117/924
Gastrointestinal disorderGastrointestinal disorders238/922185/924
PyrexiaGeneral disorders192/92257/924
SwellingGeneral disorders168/9229/924

Baseline characteristics

Age, Continuous
Age, Continuous(Years)GSK1437173A GroupPlacebo GroupTotal
Mean54.8 ± 11.755.1 ± 11.455.0 ± 11.6
Sex: Female, Male
Sex: Female, Male(Participants)GSK1437173A GroupPlacebo GroupTotal
Female342346688
Male5805781158
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)GSK1437173A GroupPlacebo GroupTotal
Geographic ancestry — African Heritage/African American152540
Geographic ancestry — American Indian or Alaskan Native202
Geographic ancestry — Asian - Central/South Asian Heritage6511
Geographic ancestry — Asian - East Asian Heritage8391174
Geographic ancestry — Asian - Japanese Heritage433881
Geographic ancestry — Asian - South East Asian Heritage181634
Geographic ancestry — White - Arabic/North African Heritage91221
Geographic ancestry — White - Caucasian/European Heritage7157121427
Geographic ancestry — Mixed Origin312556
08

Study locations

178 sites
  • GSK Investigational Site
    Duarte, California 91010, United States
  • GSK Investigational Site
    San Francisco, California 94143, United States
  • GSK Investigational Site
    Aurora, Colorado 80045, United States
  • GSK Investigational Site
    Westwood, Kansas 66205, United States
  • GSK Investigational Site
    Lexington, Kentucky 40536, United States
  • GSK Investigational Site
    Boston, Massachusetts 02111, United States
  • GSK Investigational Site
    Boston, Massachusetts 02114, United States
  • GSK Investigational Site
    Boston, Massachusetts 02115, United States
  • GSK Investigational Site
    Detroit, Michigan 48201, United States
  • GSK Investigational Site
    Minnesota, Minnesota 55455, United States
  • GSK Investigational Site
    Rochester, Minnesota 55905, United States
  • GSK Investigational Site
    Hackensack, New Jersey 07601, United States
  • GSK Investigational Site
    New York, New York 10021, United States
  • GSK Investigational Site
    Syracuse, New York 13210, United States
  • GSK Investigational Site
    Chapel Hill, North Carolina 27599, United States
  • GSK Investigational Site
    Durham, North Carolina 27705, United States
  • GSK Investigational Site
    Cleveland, Ohio 44195, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19107, United States
  • GSK Investigational Site
    Dallas, Texas 75246, United States
  • GSK Investigational Site
    Seattle, Washington 98108, United States
  • GSK Investigational Site
    Seattle, Washington 98109-1024, United States
  • GSK Investigational Site
    Marshfield, Wisconsin 54449, United States
  • GSK Investigational Site
    Darlinghurst, New South Wales 2010, Australia
  • GSK Investigational Site
    Waratah, New South Wales 2298, Australia
  • GSK Investigational Site
    Westmead, New South Wales 2145, Australia
  • GSK Investigational Site
    Woodville, South Australia 5011, Australia
  • GSK Investigational Site
    Hobart, Tasmania 7000, Australia
  • GSK Investigational Site
    Box Hill, Victoria 3128, Australia
  • GSK Investigational Site
    East Melbourne, Victoria 3002, Australia
  • GSK Investigational Site
    Heidelberg, Victoria 3084, Australia
  • GSK Investigational Site
    Parkville, Victoria 3050, Australia
  • GSK Investigational Site
    Antwerpen, 2060, Belgium
  • GSK Investigational Site
    Brugge, 8000, Belgium
  • GSK Investigational Site
    Bruxelles, 1000, Belgium
  • GSK Investigational Site
    Gent, 9000, Belgium
  • GSK Investigational Site
    Hasselt, 3500, Belgium
  • GSK Investigational Site
    Jette, 1090, Belgium
  • GSK Investigational Site
    Leuven, 3000, Belgium
  • GSK Investigational Site
    Liege, 4000, Belgium
  • GSK Investigational Site
    Sofia, Bulgaria
  • GSK Investigational Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • GSK Investigational Site
    Saint John, New Brunswick E2L 4L2, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 2M9, Canada
  • GSK Investigational Site
    Montreal, Quebec H2L 4M1, Canada
  • GSK Investigational Site
    Quebec City, Quebec G1J 1Z4, Canada
  • GSK Investigational Site
    Saskatoon, Saskatchewan S7N 4H4, Canada
  • GSK Investigational Site
    Hradec Kralove, Czechia
  • GSK Investigational Site
    Olomouc, 775 20, Czechia
  • GSK Investigational Site
    Praha 10, 100 34, Czechia
  • GSK Investigational Site
    Praha 2, 128 08, Czechia
  • GSK Investigational Site
    Tallinn, 13419, Estonia
  • GSK Investigational Site
    Helsinki, 00029, Finland
  • GSK Investigational Site
    Tampere, 33520, Finland
  • GSK Investigational Site
    Turku, 20520, Finland
  • GSK Investigational Site
    Clermont-Ferrand Cedex 1, 63003, France
  • GSK Investigational Site
    Créteil cedex, 94010, France
  • GSK Investigational Site
    Grenoble cedex 9, 38043, France
  • GSK Investigational Site
    Marseille cedex 9, 13273, France
  • GSK Investigational Site
    Montpellier cedex 5, 34295, France
  • GSK Investigational Site
    Pessac cedex, 33604, France
  • GSK Investigational Site
    Rouen cedex 1, 76038, France
  • GSK Investigational Site
    Heidelberg, Baden-Wuerttemberg 69120, Germany
  • GSK Investigational Site
    Mannheim, Baden-Wuerttemberg 68167, Germany
  • GSK Investigational Site
    Bayreuth, Bayern 95445, Germany
  • GSK Investigational Site
    Muenchen, Bayern 81545, Germany
  • GSK Investigational Site
    Wuerzburg, Bayern 97080, Germany
  • GSK Investigational Site
    Bonn, Nordrhein-Westfalen 53127, Germany
  • GSK Investigational Site
    Eschweiler, Nordrhein-Westfalen 52249, Germany
  • GSK Investigational Site
    Muenster, Nordrhein-Westfalen 48149, Germany
  • GSK Investigational Site
    Velbert, Nordrhein-Westfalen 42551, Germany
  • GSK Investigational Site
    Kiel, Schleswig-Holstein 24105, Germany
  • GSK Investigational Site
    Berlin, 10117, Germany
  • GSK Investigational Site
    Berlin, 12200, Germany
  • GSK Investigational Site
    Berlin, 12351, Germany
  • GSK Investigational Site
    Athens, 106 76, Greece
  • GSK Investigational Site
    Athens, 115 27, Greece
  • GSK Investigational Site
    Athens, 11527, Greece
  • GSK Investigational Site
    Athens, 151 23, Greece
  • GSK Investigational Site
    Thessaloniki, 57010, Greece
  • GSK Investigational Site
    Hong Kong, Hong Kong
  • GSK Investigational Site
    Tuen Mun, Hong Kong
  • GSK Investigational Site
    Hafia, 31096, Israel
  • GSK Investigational Site
    Jerusalem, 91120, Israel
  • GSK Investigational Site
    Cona (FE), Emilia-Romagna 44124, Italy
  • GSK Investigational Site
    Meldola (FC), Emilia-Romagna 47014, Italy
  • GSK Investigational Site
    Ravenna, Emilia-Romagna, Italy
  • GSK Investigational Site
    Rimini, Emilia-Romagna 47900, Italy
  • GSK Investigational Site
    Aviano (PN), Friuli-Venezia-Giulia 33081, Italy
  • GSK Investigational Site
    Udine, Friuli-Venezia-Giulia 33100, Italy
  • GSK Investigational Site
    Rozzano (MI), Lombardia 20089, Italy
  • GSK Investigational Site
    Novara, Piemonte 28100, Italy
  • GSK Investigational Site
    Fukuoka, 811-1395, Japan
  • GSK Investigational Site
    Gunma, 377-0280, Japan
  • GSK Investigational Site
    Hiroshima, 737-0023, Japan
  • GSK Investigational Site
    Hiroshima, 739-0651, Japan
  • GSK Investigational Site
    Hyogo, 650-0047, Japan
  • GSK Investigational Site
    Kumamoto, 860-0008, Japan
  • GSK Investigational Site
    Nagasaki, 856-8562, Japan
  • GSK Investigational Site
    Niigata, 951-8566, Japan

Showing the first 100 of 178 sites across 28 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Curran D, Matthews S, Rowley SD, Young JH, Bastidas A, Anagnostopoulos A, Barista I, Chandrasekar PH, Dickinson M, El Idrissi M, Heras I, Milliken ST, Monserrat Coll J, Navarro Matilla MB, Oostvogels L, Piatkowska-Jakubas B, Quiel D, Sabry W, Schwartz S, Selleslag DLD, Sullivan KM, Theunissen K, Yegin ZA, Yeh SP, Zaja F, Szer J; ZOE-HSCT Study group collaborators. Recombinant Zoster Vaccine Significantly Reduces the Impact on Quality of Life Caused by Herpes Zoster in Adult Autologous Hematopoietic Stem Cell Transplant Recipients: A Randomized Placebo-Controlled Trial (ZOE-HSCT). Biol Blood Marrow Transplant. 2019 Dec;25(12):2474-2481. doi: 10.1016/j.bbmt.2019.07.036. Epub 2019 Aug 5. PubMed 31394276 ↗
  • Bastidas A, de la Serna J, El Idrissi M, Oostvogels L, Quittet P, Lopez-Jimenez J, Vural F, Pohlreich D, Zuckerman T, Issa NC, Gaidano G, Lee JJ, Abhyankar S, Solano C, Perez de Oteyza J, Satlin MJ, Schwartz S, Campins M, Rocci A, Vallejo Llamas C, Lee DG, Tan SM, Johnston AM, Grigg A, Boeckh MJ, Campora L, Lopez-Fauqued M, Heineman TC, Stadtmauer EA, Sullivan KM; ZOE-HSCT Study Group Collaborators. Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial. JAMA. 2019 Jul 9;322(2):123-133. doi: 10.1001/jama.2019.9053. Erratum In: JAMA. 2019 Aug 27;322(8):785. doi: 10.1001/jama.2019.11467. PubMed 31287523 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2012 to primary completion in Nov 2016, 51 months.

Results were first posted in Jan 2018, 1 year 2 months after primary completion.

Of 33 industry-sponsored phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 51 months is above that.

Counting every sponsor, half of 40 studies reached it within 16 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2012
First posted
Jun 4, 2012
StartActual
Jul 13, 2012
Primary completionActual
Nov 4, 2016
CompletionActual
Feb 1, 2017
Results first posted
Jan 23, 2018
Last update
Jan 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01610414
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 4, 2012
Start date
Jul 13, 2012
Primary completion
Nov 4, 2016
Completion
Feb 1, 2017
Results posted
Jan 23, 2018
Last update
Jan 23, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Shingrix

Start the discussion